Transplantation therapies
Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.
1. A method of treating transplantation injury, comprising the steps of administering to a subject in need thereof an effective amount of Bryostatin-1, Bryostatin-1 analog or a pharmaceutically acceptable salt thereof to reduce or prevent induced neutrophil trans endothelial migration, wherein said effective amount of Bryostatin-1, Bryostatin-1 analog or a pharmaceutically acceptable salt thereof is held in a dosage form; and wherein the dosage form comprises polyalkylene glycol glyceride.
2. The method of claim 1 wherein the effective amount of Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is in an organ preservation solution at a concentration of 20 to 1000 nanograms per milliliter.
3. The method of claim 1 wherein said effective amount of Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is an amount to achieve a plasma concentration in an individual being treated for transplantation injury or in tissue or organ being prepared for transplantation of levels of 10 −7 M.
4. The method of claim 1 wherein said dosage form is an oral dosage form.
5. The method of claim 4 wherein said oral dosage form is a solid oral dosage form.
6. The method of claim 1 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbons to eighteen carbons saturated fatty acids with glycerol.
7. The method of claim 6 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000 daltons.
8. The method of claim 7 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600 daltons.
9. The method of claim 4 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 1 to 30% by weight.
10. The method of claim 4 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 10 to 20% by weight.
11. The method of claim 4 wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 2 to 25% by weight.
12. The method of claim 1 wherein said dosage form is a pharmaceutical parenteral formulation.
13. The method of claim 12 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbons to eighteen carbons saturated fatty acids with glycerol.
14. The method of claim 13 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000 daltons.
15. The method of claim 14 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600 daltons.
16. The method of claim 1 wherein said subject is a human.